 |
|
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
Yoo-Ri Chung (Chung YR), Kyoung Hwa Ha (Ha KH), Hyeon Chang Kim (Kim HC), Sang Jun Park (Park SJ), Kihwang Lee (Lee K), Dae Jung Kim (Kim DJ)
Diabetes Metab J. 2019;43(5):640-648. Published online 2019 Feb 20 DOI: https://doi.org/10.4093/dmj.2018.0137
|
|
Citations to this article as recorded by
 Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy
Jennifer Perais, Ridhi Agarwal, Jennifer R Evans, Emma Loveman, Jill L Colquitt, David Owens, Ruth E Hogg, John G Lawrenson, Yemisi Takwoingi, Noemi Lois
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model
Patricia Bogdanov, Hugo Ramos, Marta Valeri, Anna Deàs-Just, Jordi Huerta, Rafael Simó, Cristina Hernández
Biomedicines.2022; 10(2): 465. CrossRef Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Zaynab Ahmad Mouhammad, Rupali Vohra, Anna Horwitz, Anna-Sophie Thein, Jens Rovelt, Barbara Cvenkel, Pete A. Williams, Augusto Azuara-Blanco, Miriam Kolko
Frontiers in Neuroscience.2022;[Epub] CrossRef Transcriptomic Analysis Reveals That Retinal Neuromodulation Is a Relevant Mechanism in the Neuroprotective Effect of Sitagliptin in an Experimental Model of Diabetic Retinopathy
Hugo Ramos, Patricia Bogdanov, Rafael Simó, Anna Deàs-Just, Cristina Hernández
International Journal of Molecular Sciences.2022; 24(1): 571. CrossRef The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathy—A Review
Wojciech Matuszewski, Angelika Baranowska-Jurkun, Magdalena Maria Stefanowicz-Rutkowska, Katarzyna Gontarz-Nowak, Ewa Gątarska, Elżbieta Bandurska-Stankiewicz
Journal of Clinical Medicine.2021; 10(4): 705. CrossRef Effects of Fibrates on Risk of Development of Diabetic Retinopathy in Japanese Working Age Patients with Type 2 Diabetes and Dyslipidemia: a Retrospective Cohort Study
Hayato Akimoto, Yasuo Takahashi, Satoshi Asai
YAKUGAKU ZASSHI.2021; 141(5): 761. CrossRef Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
Eugene Yu-Chuan Kang, Chunya Kang, Wei-Chi Wu, Chi-Chin Sun, Kuan-Jen Chen, Chi-Chun Lai, Tien-Hsing Chen, Yih-Shiou Hwang
Journal of Clinical Medicine.2021; 10(13): 2871. CrossRef Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities
Nidhi Raval, Akshant Kumawat, Dnyaneshwar Kalyane, Kiran Kalia, Rakesh K. Tekade
Drug Discovery Today.2020; 25(5): 862. CrossRef Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
Jun Sung Moon
Diabetes & Metabolism Journal.2019; 43(6): 911. CrossRef Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
Yoo-Ri Chung, Kyoung Hwa Ha, Kihwang Lee, Dae Jung Kim
Diabetes & Metabolism Journal.2019; 43(6): 917. CrossRef
|